Lead product VSN16R in Phase I

VSN16R a novel orally active small molecule compound that has been shown in testing to date to be substantially more tolerable than existing anti-spastic agents. Preclinical studies confirm that VSN16R does not cause the flaccidity, sedation or other cognitive side-effects that are major disadvantages of baclofen, a widely used anti-spastic, and other available drugs. VSN16R is as effective as any other known agent in the EAE model, which is the gold standard model for evaluating MS treatments.

VSN16R is currently in a Phase I clinical trial to determine safety and tolerability in healthy volunteers. This first in man study of VSN16R will enrol a total of 72 healthy volunteers in a placebo-controlled, single ascending dose and multiple ascending dose design. The study is being carried out by Quintiles, the world's leading clinical research organisation.